Print Friendly, PDF & Email

NCT/Study#

NA /

BND-22-001

?A Phase 1/2, Dose Escalation And Expansion Study Of The Safety, Tolerability, And Anti-Tumor Activity Of BND-22 Administered Alone And In Combination With Pembrolizumab Or With Cetuximab In Patients With Advanced Solid Tumors

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: